Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00029445 |
Recruitment Status
:
Recruiting
First Posted
: January 14, 2002
Last Update Posted
: March 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will collect white blood cells and plasma for research on how the immune system controls HIV infection. The immune system of a very small group of HIV-infected patients, called non-progressors, has been able to control HIV for long periods without antiretroviral therapy. Some immune system-related genes important for this control have been identified in these patients. This study will examine the contribution of HLA genes B*57+, B*27+ and A*01+ to HIV disease in progressors and long-term non-progressors. (HLA type is a genetic marker of the immune system.)
HIV-infected patients 18 years of age and older with HLA types B*57+, B*27+ and/or A*01+ may be eligible for this study.
Participants will undergo apheresis-a method for collecting larger quantities of certain blood components than can safely be collected through a simple blood draw-by one of the following two methods:
- Automated pheresis - Blood is drawn through a needle placed in an arm vein and spun in a machine, separating the blood components. The white cells are extracted and the red cells, with or without plasma (liquid part of the blood), are re-infused into the donor through the same needle or a needle in the other arm. An anticoagulant (medication to prevent blood from clotting) is usually added to the blood while in the machine to prevent it from clotting during processing.
- Manual pheresis - One unit (1 pint) of blood is drawn through a needle placed in an arm vein, similar to donating a pint of whole blood. The red blood cells, with or without plasma, are separated from the rest of the blood and re-infused to the donor through the same needle. Manual pheresis will be done only when a person s estimated total blood volume or red cell count is too low to safely permit removal of blood through a pheresis machine. An adult small in size or markedly anemic, for example, may fall into this category.
Some of the blood collected through apheresis may be stored for future studies of HIV disease and immune function and for HLA testing, a genetic test of markers of the immune system. Some of the blood may be used to screen for different types of viral liver infections, such as hepatitis A, B, C, D, E, F, or G.
Condition or disease |
---|
Human Immunodeficiency Virus |
Study Type : | Observational |
Estimated Enrollment : | 400 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity |
Study Start Date : | January 4, 2002 |

- Studies of HIV-specific immunity [ Time Frame: Ongoing ]
- Cohort Natural History Study [ Time Frame: Ongoing ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
-
INCLUSION CRITERIA FOR PATIENTS NOT INCLUDED UNDER THE TREATMENT INTERRUPTION ARM:
- Adult (18 years old or older).
- Eligibility to undergo apheresis procedures; or for patients who are unable to undergo apheresis, willingness to undergo blood draw for research purposes that remain within safety guidelines established by NIH policy.
-
Willingness to give informed consent for the storage of blood or
tissue samples and HLA testing.
-
AND at least one of the following:
- An HIV-seropositive patient categorized as an LTNP as defined by clinical and laboratory criteria, regardless of HLA class I type.
- HIV-seropositive HLA B*27+, B*35+, B*44+, B*57+, B*58+ and/or A*02+ progressors.
- HIV-seropositive patients possessing sera with broadly cross-neutralizing antibody activity to HIV.
- Persons who are seronegative for HIV but are family members of seropositive patients exhibiting immunologic control of HIV.
EXCLUSION CRITERIA FOR PATIENTS NOT INCLUDED UNDER THE TREATMENT INTERRUPTION ARM:
- Pregnant women.
- Cardiovascular instability, severe anemia, inadequate venous access, severe coagulation disorder or any other condition that the Principal Investigator or Apheresis Unit staff considers a contraindication to the apheresis procedure or research blood draw.
INCLUSION CRITERIA FOR PATIENTS CONSENTING TO UNDERGO A TREATMENT INTERRUPTION:
- Subjects greater than or equal to 18 years of age.
- HIV infection confirmed by ELISA and Western blot.
- Ability to sign informed consent and willingness to comply with study requirements and clinic policies.
- In the judgment of the PI, patient has satisfactory knowledge of the benefits of continuing ART as well as the risks of discontinuing such treatment. The patient has a private physician and the decision to interrupt antiretroviral therapy, the target point (i.e. viral load or CD4+ T cell count) to reinitiate therapy, and the regimen of antiretrovirals used upon re-initiation of therapy will be made with this private physician.
- History of at least 2 months of ongoing ART, defined as a minimum three drug regimen consisting of at least two nucleoside analogs and one or two protease inhibitors or one non-nucleoside reverse transcriptase inhibitor (NNRTI) or classesone integrase inhibitor OR patients that are currently off therapy who are planning on resuming or initiating a ART regimen within the next 3 months.
- No baseline CD4+ T cell counts less than or equal to 500 cells/micro liters, with confirmation, within the last 3 months.
- Asymptomatic for significant HIV-related illnesses, such as opportunistic infections and malignancies other than mucocutaneous Kaposi s sarcoma.
- For patients on IL-2 therapy, agreement to resume ART while undergoing treatment cycles.
- Eligibility to undergo apheresis procedures.
EXCLUSION CRITERIA FOR PATIENTS CONSENTING TO UNDERGO A TREATMENT INTERRUPTION:
- Psychiatric illness that, in the opinion of the PI, might interfere with study compliance.
- Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise patient safety.
- Women who are pregnant or breastfeeding.
- Creatinine greater than 2 mg/dL.
- Platelet count less than 100,000/mm(3), hemoglobin less than 9 mg/dL, neutrophils less than 750/mm(3).
- PT or PTT (in the absence of documented anti-cardiolipin antibody) prolonged by greater than 2 seconds.
- Known underlying bleeding disorder that would preclude leukapheresis.
- Significant cardiac, pulmonary, kidney, rheumatologic, gastrointestinal, or CNS disease as detectable on routine history, physical examination, or screening laboratory studies.
- Documented history of virologic relapse in the past year following interruption of ART therapy.
- History of significant opportunistic infection or HIV-associated malignancy.
- Patient must not ever have had a total CD4 count of less than or equal to 150 cells/cubic millimeter during the year prior to enrollment. At least 2 measurements, possibly including the measurement during the screening visit and/or H&P visit, must be available.
- Due to a possible increased risk of a hypersensitivity reaction, patients on an abacavir-containing regimen will not be eligible for treatment interruption.
- Patients with chronic hepatitis B infection requiring receiving treatment with 3TC (lamivudine), adefovir or tenofovir for suppression are not eligible for this study.
- Cardiovascular instability, severe anemia, inadequate venous access, severe coagulation disorder or any other condition that the Principal Investigator or Apheresis Unit staff considers a contraindication to the apheresis procedure or research blood draw.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029445
Contact: April Poole, R.N. | (301) 435-8007 | pooleal@mail.nih.gov | |
Contact: Stephen A Migueles, M.D. | (301) 496-7090 | smigueles@niaid.nih.gov |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov |
Principal Investigator: | Stephen A Migueles, M.D. | National Institute of Allergy and Infectious Diseases (NIAID) |
Additional Information:
Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00029445 History of Changes |
Other Study ID Numbers: |
020086 02-I-0086 |
First Posted: | January 14, 2002 Key Record Dates |
Last Update Posted: | March 29, 2018 |
Last Verified: | March 7, 2018 |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
HLA B5701 LTNP Neutralizing Antibodies CTL |
Virus Restriction HIV HIV-Infected Long Term Nonprogressors |
Additional relevant MeSH terms:
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections |
RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases |